BIOCYTOGEN
8.3.2023 14:26:40 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom